Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

EU Approves Vertex Pharma's KALYDECO For Cystic Fibrosis - Quick Facts

RELATED NEWS
Trade VRTX now with 
7/27/2012 4:20 AM ET

Vertex Pharmaceuticals Inc. (VRTX: Quote) said the European Commission has approved KALYDECOTM for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator or CFTR gene. KALYDECO is the first medicine to target the underlying cause of the disease in these patients.

Cystic fibrosis is a rare genetic disease caused by defective or missing CFTR proteins resulting from mutations in the CFTR gene.

KALYDECO helps the defective CFTR protein function more normally in patients with the G551D mutation. An estimated 1,100 people in Europe have the G551D mutation. The European Approval is based on positive findings from two global Phase 3 trials in which KALYDECO showed significant and sustained improvements in breathing, weight gain and other measures of disease for people ages 6 and older with this specific genetic mutation, compared to placebo.

Further, people who took KALYDECO were 55 percent less likely to have pulmonary exacerbations, or periods of worsening in the signs and symptoms of the disease that often require treatment with antibiotics and hospital visits, than those who received placebo, the company noted.

The KALYDECO approval comes two months after the European Committee for Medicinal Products for Human Use issued a positive opinion and is the first European approval for Vertex.

Register
To receive FREE breaking news email alerts for Vertex Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Chipmaker Advanced Micro Devices Inc. said Thursday after the markets closed that its first quarter loss narrowed from last year, helped by strong revenue growth in its graphics and visual solutions business. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. After trending higher over the past few sessions, stocks showed a lack of direction throughout the trading day on Thursday. The major averages spent the session bouncing back and forth across the unchanged line before ending the day mixed. While the major averages closed on opposite sides of the unchanged line, they all showed only modest moves. U.S. Secretary Of State John Kerry said Thursday that he and his counterparts from Russia, Ukraine and the European Union have reached an agreement on a preliminary plan for ending the ongoing crisis in Ukraine. Kerry was speaking at the end of the Ukraine contact group's first meeting, comprising the foreign ministers of Russia, Ukraine, the EU and the U.S., in the Swiss city of Geneva.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.